Table 1 Correlation of Pokemon expression with clinicopathological parametersa
From: Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression
| Â | Pokemon(n= 182) | Â | |||
|---|---|---|---|---|---|
Variables | 3 | 2 | 1 | 0 | Pvalue |
Subtotal, n (%) | 72 (39.6) | 69 (37.9) | 17 (9.3) | 24 (13.2) | Â |
Age, yr (%) | Â | Â | Â | Â | 0.2451 |
   >50 | 58 (40.8) | 55 (38.7) | 13 (9.2) | 16 (11.3) |  |
   ≤50 | 13 (33.3) | 14 (35.9) | 4 (10.3) | 8 (20.5) |  |
Tumor types, n (%) | Â | Â | Â | Â | 0.8733 |
   Colloid | 3 (37.5) | 3 (37.5) | 1 (12.5) | 1 (12.5) |  |
   Ductal | 35 (47.9) | 26 (35.6) | 5 (6.8) | 7 (9.6) |  |
   Lobular | 14 (53.8) | 8 (30.8) | 3 (11.5) | 1 (3.8) |  |
Tumor size, cm3 (%) | Â | Â | Â | Â | 0.0148 |
   >2 | 47 (42.7) | 46 (41.8) | 9 (8.2) | 8 (7.3) |  |
   ≤2 | 23 (33.8) | 22 (32.3) | 8 (11.8) | 15 (22.1) |  |
Node metastasis, n (%) | Â | Â | Â | Â | 0.0014 |
   Positive | 49 (44.1) | 38 (34.2) | 8 (7.2) | 16 (14.4) |  |
   Negative | 22 (31.9) | 30 (43.5) | 9 (13.0) | 8 (11.6) |  |
Nuclear grade, n (%) | Â | Â | Â | Â | 0.057 |
   1 | 5 (23.8) | 9 (42.6) | 2 (9.5) | 5 (23.8) |  |
   2 | 40 (40.4) | 38 (38.4) | 12 (12.1) | 9 (9.1) |  |
   3 | 25 (45.5) | 20 (38.4) | 3 (12.1) | 7 (9.1) |  |
ER, n (%) | Â | Â | Â | Â | 0.429 |
   Positive | 38 (37.6) | 39 (38.6) | 11 (10.9) | 13 (12.9) |  |
   Negative | 34 (42.0) | 30 (37.0) | 6 (7.4) | 11 (13.6) |  |
PR, n (%) | Â | Â | Â | Â | 0.3444 |
   Positive | 41 (40.2) | 34 (33.3) | 14 (13.7) | 13 (12.8) |  |
   Negative | 31 (38.8) | 35 (43.8) | 3 (3.7) | 11 (14.7) |  |
HER2, n (%) | Â | Â | Â | Â | 0.2309 |
   Positive | 31 (38.7) | 28 (35.0) | 7 (8.8) | 14 (17.5) |  |
   Negative | 41 (38.3) | 41 (38.3) | 11 (10.3) | 14 (13.1) |  |